ImmunID and MSK sign master collaboration agreement

ImmunID, a French company that seeks to personalise immunotherapy for cancer patients, has signed a master collaboration agreement with the world’s oldest and largest private cancer centre — the Memorial Sloan Kettering Cancer Center (MSK) in New York.

ImmunID’s ImmunTraCkeR assay provides information on a patient’s immune status based on the T lymphocyte diversity identified from a simple liquid biopsy. From this, it is able to evaluate the clinical benefit or risk of treatment with immunotherapies.

The collaboration aims to validate the clinical utility of the assay to predict response to cancer immunotherapy and, in particular, to immune checkpoint agents in solid tumours. It is based on a proof of concept published by the companies in the Journal for ImmunoTherapy of Cancer showing that analysis using ImmunTraCkeR is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.

“This master agreement will allow not only to further validate ImmunTraCkeR’s predictive power for anti-CTLA4 and anti-PD1 in metastatic melanoma, but also to expand ImmunTraCkeR’s clinical utility to ‘next generation’ immuno-oncology approaches and in additional tumour types,” said Dr Nicolas Pasqual, co-founder and chief science officer of ImmunID. “We are very proud to be extending our collaboration with Dr Michael Postow and the team of the Melanoma and Immunotherapeutics Service at MSK.”